Health-related quality of life of men with primary osteoporosis and its changes after bisphosphonates treatment

• Published in: BMC musculoskeletal disorders Vol. 24; no. 1; p. 309
• Main Authors: Zhao, Di-Chen, Lin, Xiao-Yun, Hu, Jing, Zhou, Bing-Na, Zhang, Qian, Wang, Ou, Jiang, Yan, Xia, Wei-Bo, Xing, Xiao-Ping, Li, Mei
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 19.04.2023; BioMed Central; BMC
• Subjects: Alendronic acid; Bisphosphonates; Bone Density; Bone diseases; Bone Diseases, Metabolic - drug therapy; Bone mineral density; Bones; Care and treatment; Collagen (type I); Density; Diagnosis; Diphosphonates - therapeutic use; Drugs; Endocrinology; Female; Fractures; Fractures, Bone; Health aspects; HRQoL; Humans; Male; Males; Men; Metabolism; Mortality; Musculoskeletal diseases; Osteopenia; Osteoporosis; Osteoporosis - drug therapy; Patients; Procollagen; Quality of Life; Questionnaires; Serum levels; SF-36; Spine; Womens health; Zoledronic acid; China; Osteoporosis; HRQoL; Males; Bisphosphonates; SF-36
• ISSN: 1471-2474; 1471-2474
• DOI: 10.1186/s12891-023-06397-8

Osteoporosis leads to more serious consequences in men than in women, but less is known about its impacts on health-related quality of life (HRQoL) of men, and whether the anti-osteoporosis treatment can improve HRQoL of men with osteopenia/osteoprosis. We enrolled men with primary osteoporosis and age-matched healthy controls. We collected medical history, serum levels of carboxyl-terminal type I collagen telopeptide, procollagen type I propeptides, and bone mineral density of patients. All patients and controls completed the short-form 36 (SF-36) questionnaires. Changes in HRQoL of osteopenia/osteoporosis men were prospectively evaluated after alendronate or zoledronic acid treatment. A total of 100 men with primary osteoporosis or osteopenia and 100 healthy men were included. The patients were divided into three subgroups: osteopenia (n = 35), osteoporosis (n = 39) and severe osteoporosis (n = 26). Men with osteoporosis or severe osteoporosis had impaired HRQoL in domains of physical health compared to healthy controls. HRQoL scores in physical health related domains of patients with severe osteoporosis were significantly lower compared to healthy controls, and were the poorest among the three subgroups of patients. Fragility fracture history was correlated with lower SF-36 scores about physical health. In 34 men with newly diagnosed osteoporosis receiving bisphosphonates treatment, HRQoL scores were significantly improved in domains of physical health after treatments. The HRQoL is significantly impaired in men with osteoporosis, and the more severe the osteoporosis, the poorer the HRQoL. Fragility fracture is an important influencing factor of deteriorated HRQoL. Bisphosphonates treatment is beneficial to improve HRQoL of osteopenia/osteoporosis men.